Fundz

Lobe Sciences Ltd. secures US$6 million through a private placement to support drug development. This funding will be used to advance their Conjugated Psilocin™ technology and clinical studies.

PRIVATEApr 14, 2025

Amount Raised

$6 Million

Round Type

Series A

BiotechnologyHealth CareMedicalTherapeutics

Description

Lobe Sciences Ltd. has announced a strategic private placement of US$6 million through its subsidiary, Cynaptec Pharmaceuticals. This investment may include an additional US$20 million if specific clinical milestones are met. The funding will support preclinical research and Phase 1 and Phase 2a clinical studies for their novel drug technology

Quick answer

Lobe Sciences raised $6 Million in a Series A round, dated April 14, 2025.

How much did Lobe Sciences raise?
Lobe Sciences raised $6 Million in a Series A round on April 14, 2025.
What does Lobe Sciences do?
Lobe Sciences is a biopharmaceutical company dedicated to advancing innovative technologies for the development of urgently needed treatments for orphan and rare diseases.
Where is Lobe Sciences based and how big is it?
Fundz records about 3 employees.
Who are the decision-makers at Lobe Sciences?
Fundz holds 3 contacts at Lobe Sciences, including the Chief Financial Officer. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who to call at Lobe Sciences, and when

A new round usually means Lobe Sciences is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Lobe Sciences raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Lobe Sciences, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Lobe Sciences. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Lobe Sciences

About

Lobe Sciences is a biopharmaceutical company dedicated to advancing innovative technologies for the development of urgently needed treatments for orphan and rare diseases. The company commercializes Altemia® MF, a medical food formulated to address deficiencies commonly associated with sickle cell disease. Additionally, Lobe Sciences is developing S100, an orphan drug candidate aimed at treating sickle cell disease. Through Cynaptec, Lobe maintains an interest in the development of Conjugated Psilocin™, targeting neurology and psychiatric conditions. The company also retains Alera Pharma, Inc. as a wholly owned subsidiary, which may be utilized for future initiatives unrelated to Conjugated Psilocin™.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Lobe Sciences raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

3 contacts
Verified contactsDavid K., Chief Financial Officer hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Lobe Sciences's next move

See what Strategic adds

Funding Insights

What this usually means
Typical timeline to Series B
Series A companies typically raise their next round in 10-18 months

Lobe Sciences raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.